Earnings ·
Takeda reports H1 net profit of JPY 305.7 billion, up 171.6%, on lower amortization
TKPHFTakeda Pharmaceutical Co Ltd
Takeda Pharmaceutical reported a 171.6% surge in first-half net profit to JPY 305.7 billion for the period ended September 30, 2026, driven by a significant decline in amortization and impairment losses on intangible assets. Revenue increased 8.4% to JPY 2,407.0 billion, though constant exchange rate revenue declined slightly due to loss of exclusivity impacts offsetting growth in key brands like ENTYVIO and ADCETRIS. Operating profit rose 60.4% to JPY 406.7 billion. The company also revised its full-year management guidance downward, projecting a low-single digit decline in Core Revenue and a low-teens percent drop in Core EPS for the fiscal year ending March 31, 2027. Takeda Pharmaceutical Company Limited is a global pharmaceutical company focused on prescription medicines, vaccines, and plasma-derived therapies.